Adjuvant Dabrafenib plus Trametinib for Stage III Melanoma | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Adjuvant Dabrafenib plus Trametinib for Stage III Melanoma
Related Articles
FDA Grants Orphan Drug Designation to Antibiotic for NTM Infections
The novel benzoxazole antibiotic is being developed for treating non-tuberculous mycobacteria (NTM) infections.
FDA Clears Simeox 200 Airway Clearance Device
Inogen Inc has received FDA 510(k) clearance for the Simeox 200 airway clearance device, designed to enhance bronchial drainage.
Detecting Alpha-1 Antitrypsin Deficiency: Current State, Impediments, Opportunities, and Future Directions
Alpha-1 antitrypsin deficiency (AATD) is an underrecognized condition with only a small minority of affected individuals diagnosed, long delays between initial symptoms and diagnosis, and…
Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation. Mechanistic Implications for Desquamative Interstitial Pneumonitis
Impaired airway epithelial barrier and decreased expression of E-cadherin are key features of severe asthma. As a gatekeeper of the mucosa, E-cadherin can be cleaved…
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for…
Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access | NEJM
A new era of long-acting antiretrovirals for HIV treatment and prevention demands a nonlinear approach to global access with faster sharing of technology, decentralized production,…
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma | NEJM
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemoth…
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC | NEJM
Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal g…
Potential Health Policy Administrative Actions in the Second Trump Administration | KFF
Potential health policy administrative actions under the incoming Trump administration based on campaign positions and statements by President-elect Trump, President Trump’s record during his first…
New Campaign Aims to Help Young People Stick to Their New Year’s Resolution to Quit Nicotine
Truth Initiative has launched the Outsmart Nicotine campaign, offering resources to support young adults in their quit resolutions for 2025.